253 related articles for article (PubMed ID: 35232410)
1. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
[TBL] [Abstract][Full Text] [Related]
2. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.
Memon K; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Gates VL; Atassi B; Newman S; Omary RA; Benson AB; Salem R
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):887-94. PubMed ID: 22137020
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
4. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ;
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085
[TBL] [Abstract][Full Text] [Related]
5. Survival and Toxicities after
Emmons EC; Bishay S; Du L; Krebs H; Gandhi RT; Collins ZS; O'Hara R; Akhter NM; Wang EA; Grilli C; Brower JS; Peck SR; Petroziello M; Abdel Aal AK; Golzarian J; Kennedy AS; Matsuoka L; Sze DY; Brown DB
Radiology; 2022 Oct; 305(1):228-236. PubMed ID: 35762890
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.
Gordon AC; Gradishar WJ; Kaklamani VG; Thuluvath AJ; Ryu RK; Sato KT; Gates VL; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2014 Oct; 25(10):1523-32, 1532.e1-2. PubMed ID: 25156827
[TBL] [Abstract][Full Text] [Related]
7. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.
Fan KY; Wild AT; Halappa VG; Kumar R; Ellsworth S; Ziegler M; Garg T; Rosati LM; Su Z; Hacker-Prietz A; Pawlik TM; Cosgrove DP; Hong KK; Kamel IR; Geschwind JF; Herman JM
Contemp Clin Trials; 2016 Sep; 50():143-9. PubMed ID: 27520932
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis.
Gonsalves CF; Eschelman DJ; Adamo RD; Anne PR; Orloff MM; Terai M; Hage AN; Yi M; Chervoneva I; Sato T
Radiology; 2019 Oct; 293(1):223-231. PubMed ID: 31453767
[TBL] [Abstract][Full Text] [Related]
11. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
12. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis.
Ludwig JM; Ambinder EM; Ghodadra A; Xing M; Prajapati HJ; Kim HS
Cardiovasc Intervent Radiol; 2016 Jul; 39(7):1007-14. PubMed ID: 26964779
[TBL] [Abstract][Full Text] [Related]
13. Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C).
Goswami P; Adeniran OR; K Frantz S; Matsuoka L; Du L; Gandhi RT; Collins ZS; Matrana MR; Petroziello M; Brower JS; Sze DY; Kennedy AS; Golzarian J; Wang EA; Brown DB
BMC Gastroenterol; 2022 Nov; 22(1):467. PubMed ID: 36396989
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
[TBL] [Abstract][Full Text] [Related]
15. Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases.
Smits ML; van den Hoven AF; Rosenbaum CE; Zonnenberg BA; Lam MG; Nijsen JF; Koopman M; van den Bosch MA
PLoS One; 2013; 8(7):e69448. PubMed ID: 23894481
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.
Mouli S; Memon K; Baker T; Benson AB; Mulcahy MF; Gupta R; Ryu RK; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2013 Aug; 24(8):1227-34. PubMed ID: 23602420
[TBL] [Abstract][Full Text] [Related]
17. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
Kousik V; Promila P; Verma R; Gupta A
Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
[TBL] [Abstract][Full Text] [Related]
18. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
[TBL] [Abstract][Full Text] [Related]
19. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.
Martin LK; Cucci A; Wei L; Rose J; Blazer M; Schmidt C; Khabiri H; Bloomston M; Bekaii-Saab T
Clin Colorectal Cancer; 2012 Sep; 11(3):195-9. PubMed ID: 22277350
[TBL] [Abstract][Full Text] [Related]
20. Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
Kim AY; Frantz S; Brower J; Akhter N
J Vasc Interv Radiol; 2019 Mar; 30(3):298-304.e2. PubMed ID: 30819469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
